GlassScriptPhysician profile
Timmy Cheng
NPI 1295078764
$16,487.78
in general payments reported to CMS, 2019-2025
17 companies · $1,064 in 2025
The $1,064 reported for 2025 was more than what 78% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $58.88 · 2021: $338 · 2022: $13K · 2023: $557 · 2024: $753 · 2025: $1,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,373.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,976.84 | 2022 | |
| Glaxosmithkline, LLC. | $2,064.68 | 2021-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $299.77 | 2020-2022 | |
| Philips North America LLC | $225.22 | 2019-2025 | Vest Therapy Und |
| Genzyme Corporation | $224.21 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.60 | 2022-2025 | Ofev |
| Sun Pharmaceutical Industries INC. | $124.06 | 2019 | |
| Dompe US, INC. | $97.97 | 2024 | Oxervate |
| Genentech USA, INC. | $89.90 | 2022-2023 | |
| Verona Pharma, INC. | $64.69 | 2025 | Ohtuvayre |
| Genentech, INC. | $45.55 | 2022 | |
| Liquidia Technologies, INC. | $33.89 | 2025 | Yutrepia |
| Abiomed | $30.85 | 2019 | |
| Alnylam Pharmaceuticals INC. | $26.54 | 2023 | Amvuttra |
| United Therapeutics Corporation | $20.91 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $16.10 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timmy Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.